(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026863 A1

(51) International Patent Classification[7]: C07D 413/14, 417/14, 419/14, 413/04, 417/04, A61P 35/00

(21) International Application Number:
PCT/IB2003/003823

(22) International Filing Date:
8 September 2003 (08.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/412,120	18 September 2002 (18.09.2002)	US
60/471,265	16 May 2003 (16.05.2003)	US
60/484,581	2 July 2003 (02.07.2003)	US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **BLUMBERG, Laura, Cook** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **MUNCHHOF, Michael, John** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS



(57) Abstract: Novel thiazole derivatives of formula I a - c, intermediates fo their preparation, pharmaceutical compositions containing them and their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor ("TGF")-βsignaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.

WO 2004/026863 A1

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

(88) **Date of publication of the revised international search report:** 21 April 2005

(15) **Information about Correction:**
see PCT Gazette No. 16/2005 of 21 April 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.